Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
814
datasets available to search
ShareScore release 0.9.0
Dataset results
814 results for “pancreatic adenocarcinoma”
Alcohol-induced C/EBP β-driven VIRMA decreases oxidative stress and promotes pancreatic ductal adenocarcinoma growth and metastasis via the m6A/YTHDF2/SLC43A2 pathway
GEO Series GSE272638. Homo sapiens. 10 samples. Type: Expression profiling by high throughput sequencing; Other.
Comparative transcriptome analysis of Ptf1aCre;Kras,Brg1-/- vs. Ptf1a;Kras;p53+/- subcutaneous pancreatic ductal adenocarcinoma
GEO Series GSE52332. Mus musculus. 2 samples. Type: Expression profiling by high throughput sequencing.
FOLFIRINOX Plus Nivolumab Promotes Irregular Intra-Tumoral Lymphoid Aggregates in Borderline Resectable Pancreatic Adenocarcinoma: A Phase 1 Trial
GEO Series GSE313101. Homo sapiens. 37 samples. Type: Expression profiling by high throughput sequencing.
mRNA stability factor HuR promotes immune evasion in pancreatic ductal adenocarcinoma
GEO Series GSE287307. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Single-cell RNA sequencing combined with multiplex immunofluorescence probes the role of MFAP5+ fibroblasts in the microenvironment of pancreatic ductal adenocarcinoma.
GEO Series GSE288067. Homo sapiens. 1 samples. Type: Other.
Disruption of Fibroblast MYD88 Signaling Promotes Antitumor Immunity in Pancreatic Ductal Adenocarcinoma [scRNAseq_col1a1myd88]
GEO Series GSE289400. Mus musculus. 3 samples. Type: Expression profiling by high throughput sequencing.
PI3Kδ Inhibition Modulates the Innate Inflammatory Response in Pancreatic Ductal Adenocarcinoma and Normalizes Aberrant Metabolism Associated with Cachexia
GEO Series GSE59757. Mus musculus. 26 samples. Type: Expression profiling by high throughput sequencing.
Serotonin effect on Bxpc-3 pancreatic adenocarcinoma cell line.
GEO Series GSE81355. Homo sapiens. 6 samples. Type: Expression profiling by array.
Organoids derived from pancreatic adenocarcinoma patients share morphological and genetic features with the primary tumor
GEO Series GSE114455. Homo sapiens. 42 samples. Type: Expression profiling by high throughput sequencing.
Circadian transcriptome of pancreatic adenocarcinoma unravels chronotherapeutic targets.
GEO Series GSE262627. Homo sapiens. 68 samples. Type: Expression profiling by high throughput sequencing.
Schwann Cells Shape Tumor Cells and Cancer-Associated Fibroblasts in the Pancreatic Ductal Adenocarcinoma Microenvironment
GEO Series GSE201601. Homo sapiens. 10 samples. Type: Expression profiling by high throughput sequencing.
The effect of depletion of VPAC2 on gene expression in Panc02 Pancreatic Ductal Adenocarcinoma cell line
GEO Series GSE248409. Mus musculus. 9 samples. Type: Expression profiling by high throughput sequencing.
Methylated DNA immunoprecipitation coupled with NimbleGen's array to identify methylated genes in pancreatic ductal adenocarcinoma
GEO Series GSE44738. Homo sapiens. 2 samples. Type: Methylation profiling by genome tiling array.
PLXDC1+ tumor-associated pancreatic stellate cells promote desmoplastic and immunosuppressive niche in pancreatic ductal adenocarcinoma
<p>This file containing the seurat object of scRNA-seq data from ICB treatment corhort (part of clinical trial: NCT05201729).</p>
Dataset related to article "Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival"
<p>Dataset related to article "Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival "</p> <p> </p> <p>Abstract</p> <p><strong>Background: </strong>It is unclear whether invasive intraductal papillary mucinous neoplasm (IPMN) has different clinical and prognostic characteristics, beyond histological factors, when compared to pancreatic ductal adenocarcinoma (PDAC).</p> <p><strong>Aims: </strong>compare prognostic features of resected PDAC and invasive IPMN METHODS: A retrospective study of patients resected for PDAC or invasive IPMN realized at Humanitas Cancer Center's Pancreatic Surgery Unit, Milan, Italy, between 2010 and 2016. Data recorded included patient demographics, onset symptoms, preoperative health status, tumor features, histology and surgical characteristics. Overall survival was estimated using Kaplan-Meier and prognostic factors for survival were assessed by multivariate Cox regression.</p> <p><strong>Results: </strong>A total of 332 patients were included (PDAC, n = 289; invasive IPMN, n = 43). Patients with invasive IPMN had better overall survival than PDAC patients (median: 76.6 versus 25.6 months; 5-year OS rate: 65.4% vs. 14.2%; p < 0.001). PDAC histology was associated with a significantly higher risk of death than IPMN (hazard ratio 1.815, 95% CI: 1.02, 3.24; p = 0.044). Survival was also worse with PDAC in early-stage disease (IA-IB-IIA, N0). In multivariate analysis, independent predictors of worse survival included perineural invasion, preoperative ASA physical status ≥3 and pain at diagnosis.</p> <p><strong>Conclusions: </strong>Patients with IPMN had a better prognosis than PDAC patients, regardless of disease stage.</p>
Mechanism of Enhancing Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma with Paricalcitol and Hydroxychloroquine: A Single Cell RNA Sequencing - PART2
<p><span>Pancreatic ductal adenocarcinoma (PDAC) boasts a dismal five-year survival rate of less than 15%, mainly due to therapy resistance. Recent studies have highlighted hydroxychloroquine (H) and paricalcitol (P), reducing stromal density and enhancing PDAC sensitivity to chemotherapy. This investigation aimed to elucidate the molecular impacts of combining H and P, focusing on their ability to sensitize PDAC to chemotherapy. <em>In vitro</em> and <em>in vivo</em> experiments demonstrated that the HP combination significantly (p<0.001) enhanced gemcitabine (G) effects, validated in orthotopic mouse models and patient-derived xenografts (PDX). Mechanistically, GPH induced cell death via the vitamin D receptor pathway upregulated autophagy and ER stress-related transcripts and suppressed mTOR signaling. Single-cell (sc) RNAseq analyses showed GPH increased quiescent cancer associated fibroblasts and reduced autophagy related transcripts. GPH treatment modulated T-cell populations favoring antitumor immunity. Findings from clinical trial patient biopsies underscored these effects, highlighting GPH's potential as a therapeutic adjunct in PDAC management (NCT04524702).</span></p>
Mechanism of Enhancing Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma with Paricalcitol and Hydroxychloroquine: A Single Cell RNA Sequencing - Part3
<p><span>Pancreatic ductal adenocarcinoma (PDAC) boasts a dismal five-year survival rate of less than 15%, mainly due to therapy resistance. Recent studies have highlighted hydroxychloroquine (H) and paricalcitol (P), reducing stromal density and enhancing PDAC sensitivity to chemotherapy. This investigation aimed to elucidate the molecular impacts of combining H and P, focusing on their ability to sensitize PDAC to chemotherapy. <em>In vitro</em> and <em>in vivo</em> experiments demonstrated that the HP combination significantly (p<0.001) enhanced gemcitabine (G) effects, validated in orthotopic mouse models and patient-derived xenografts (PDX). Mechanistically, GPH induced cell death via the vitamin D receptor pathway upregulated autophagy and ER stress-related transcripts and suppressed mTOR signaling. Single-cell (sc) RNAseq analyses showed GPH increased quiescent cancer associated fibroblasts and reduced autophagy related transcripts. GPH treatment modulated T-cell populations favoring antitumor immunity. Findings from clinical trial patient biopsies underscored these effects, highlighting GPH's potential as a therapeutic adjunct in PDAC management (NCT04524702).</span></p>
Mechanism of Enhancing Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma with Paricalcitol and Hydroxychloroquine: A Single Cell RNA Sequencing - Part4
<p><span>Pancreatic ductal adenocarcinoma (PDAC) boasts a dismal five-year survival rate of less than 15%, mainly due to therapy resistance. Recent studies have highlighted hydroxychloroquine (H) and paricalcitol (P), reducing stromal density and enhancing PDAC sensitivity to chemotherapy. This investigation aimed to elucidate the molecular impacts of combining H and P, focusing on their ability to sensitize PDAC to chemotherapy. <em>In vitro</em> and <em>in vivo</em> experiments demonstrated that the HP combination significantly (p<0.001) enhanced gemcitabine (G) effects, validated in orthotopic mouse models and patient-derived xenografts (PDX). Mechanistically, GPH induced cell death via the vitamin D receptor pathway upregulated autophagy and ER stress-related transcripts and suppressed mTOR signaling. Single-cell (sc) RNAseq analyses showed GPH increased quiescent cancer associated fibroblasts and reduced autophagy related transcripts. GPH treatment modulated T-cell populations favoring antitumor immunity. Findings from clinical trial patient biopsies underscored these effects, highlighting GPH's potential as a therapeutic adjunct in PDAC management (NCT04524702).</span></p>
Dataset related to article "Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma"
<p>This record contains data related to article “Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma”</p> <p><strong>Background: </strong> The different oncological outcomes of invasive intraductal papillary mucinous neoplasm (I-IPMN) and pancreatic ductal adenocarcinoma (PDAC) are debated. This study aimed to compare disease recurrence patterns and histopathological characteristics in patients with resected I-IPMN and PDAC.</p> <p><strong>Methods: </strong> Consecutive patients undergoing surgical resection for stage I-III I-IPMN or PDAC between 2010 and 2016 were retrospectively analyzed. Patients treated with neoadjuvant therapy or resected for Tis neoplasia were excluded. All surgical specimens were re-staged according to AJCC-8th-edition.</p> <p><strong>Results: </strong> A total of 330 patients were included, of whom 43 had I-IPMN and 287 had PDAC. Median follow-up time was 26.7 (1.3-92.3) months and estimated median disease-free survival (DFS) was 60.3 months (47.2-73.4) for I-IPMN and 23.8 (19.3-28.2) months for PDAC (p < 0.001). During follow-up, 32.6% of I-IPMN and 67.9% of PDAC patients experienced recurrence (p < 0.001). The sites of first recurrence were the lungs (38.5% vs 13.1%, p = 0.027), liver (28.6% vs 45.0%, p = 0.180) and local (15.4% vs 36.6%, p = 0.101) for I-IPMN and PDAC, respectively. At multivariate analysis, I-IPMN histology remained an independent predictive factor for longer DFS (OR 0.528, CI 95% 0.278-1.000, p = 0.050), regardless of stage or adjuvant chemotherapy. I-IPMN and PDAC differed in rates of neuroinvasion (51.2% vs 97.2%) and positive lymph node status (N+) (46.5% vs 82.7%), especially in patients with lower T status.</p> <p><strong>Conclusion: </strong> I-IPMN showed a different recurrence pattern compared to PDAC, with a higher lung tropism, and longer DFS. This different biological behavior is associated with lower rates of neuroinvasion and nodal involvement, especially in early-stage disease.</p>
Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma
ClinicalTrials.gov study NCT07083479. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.